Citations

Clear

3138 citation(s) found for "Smith, AM".

Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA)
Aravanis, Alexander A., Oxnard, Geoffrey R. , Maddala, Tara, Venn, Oliver, Jamshidi, Arash , Shen, Ling , Amini, Hamed , Beausang, John F., Betts, Craig, Civello, Daniel, Davydov, Konstantin , Fazullina, Saniya, Filippova, Darya , Gnerre, Sante, Gross, Samuel, Hou, Chenlu, Jiang, Roger, Jung, Byoungsok , Melton, Collin, Nautiyal, Shivani , Newman, Joshua, Nicolaou, Cosmos , Rava, Richard P., Sakarya, Onur, Satya, Ravi Vijaya, Shojaee, Seyedmehdi, Steffen, Kristan K., Valouev, Anton, Xu, Hui , Yue, Jeanne, Baselga, José, Lapham, Rosanna L., Davis, Daron G., Richards, Donald, Seiden, Michael V., Yeatman, Timothy J. , Tibshirani, Robert , Curtis, Christina , Plevritis, Sylvia K. , Williams, Richard T. , Hartman, Anne‐Renee , Liu, Minetta C. , Aravanis, Alexander M. , Hubbell, Earl , Davydov, Konstantin, Gross, Samuel, Jiang, Roger, Kurtzman, Kathryn N. , Newman, Jonathan D , Newman, Joshua, Zhang, Nan , Smith, David A. B. , Swanton, Charles , Klein, Eric A.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-343-LB-343

10.1158/1538-7445.am2018-lb-343 Get It

Abstract CCGA [NCT02889978] is the largest study of cfDNA-based early cancer detection; the first CCGA learnings from multiple cfDNA assays are reported here. This prospective, multi-center, observational study has enrolled 10,012 of 15,000 demographically-balanced participants at 141 sites. Blood was collected from participants with newly diagnosed therapy-naive cancer (C, case) and participants without a diagnosis of cancer (noncancer [NC], control) as defined at enrollment. This preplanned substudy included 878 cases, 580 controls, and 169 assay controls (n=1627) across 20 tumor types and all clinical stages. All samples were analyzed by: 1) Paired cfDNA and white blood cell (WBC)-targeted sequencing (60,000X, 507 gene panel); a joint caller removed WBC-derived somatic variants and residual technical noise; 2) Paired cfDNA and WBC whole-genome sequencing (WGS; 35X); a novel machine learning algorithm generated cancer-related signal scores; joint analysis identified shared events; and 3) cfDNA whole-genome bisulfite sequencing (WGBS; 34X); normalized scores were generated using abnormally methylated fragments. In the targeted assay, non-tumor WBC-matched cfDNA somatic variants (SNVs/indels) accounted for 76% of all variants in NC and 65% in C. Consistent with somatic mosaicism (i.e., clonal hematopoiesis), WBC-matched variants increased with age; several were non-canonical loss-of-function mutations not previously reported. After WBC variant removal, canonical driver somatic variants were highly specific to C (e.g., in EGFR and PIK3CA, 0 NC had variants vs 11 and 30, respectively, of C). Similarly, of 8 NC with somatic copy number alterations (SCNAs) detected with WGS, 4 were derived from WBCs. WGBS data revealed informative hyper- and hypo-fragment level CpGs (1:2 ratio); a subset was used to calculate methylation scores. A consistent “cancer-like” signal was observed in <1% of NC participants across all assays (representing potential undiagnosed cancers). An increasing trend was observed in NC vs stages I-III vs stage IV (nonsyn. SNVs/indels per Mb [Mean±SD] NC: 1.01±0.86, stages I-III: 2.43±3.98; stage IV: 6.45±6.79; WGS score NC: 0.00±0.08, I-III: 0.27±0.98; IV: 1.95± 2.33; methylation score NC: 0±0.50; I-III: 1.02±1.77; IV: 3.94±1.70). These data demonstrate the feasibility of achieving >99% specificity for invasive cancer, and support the promise of cfDNA assay for early cancer detection. Additional data will be presented on detected plasma:tissue variant concordance and on multi-assay modeling. Citation Format: Alexander A. Aravanis, Geoffrey R. Oxnard, Tara Maddala, Earl Hubbell, Oliver Venn, Arash Jamshidi, Ling Shen, Hamed Amini, John A. Beausang, Craig Betts, Daniel Civello, Konstantin Davydov, Saniya Fazullina, Darya Filippova, Sante Gnerre, Samuel Gross, Chenlu Hou, Roger Jiang, Byoungsok Jung, Kathryn Kurtzman, Collin Melton, Shivani Nautiyal, Jonathan Newman, Joshua Newman, Cosmos Nicolaou, Richard Rava, Onur Sakarya, Ravi Vijaya Satya, Seyedmehdi Shojaee, Kristan Steffen, Anton Valouev, Hui Xu, Jeanne Yue, Nan Zhang, Jose Baselga, Rosanna Lapham, Daron G. Davis, David Smith, Donald Richards, Michael V. Seiden, Charles Swanton, Timothy J. Yeatman, Robert Tibshirani, Christina Curtis, Sylvia K. Plevritis, Richard Williams, Eric Klein, Anne-Renee Hartman, Minetta C. Liu. Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-343.
Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3
O’Shaughnessy, Joyce , Forrester, Tammy , Goetz, Matthew P. , Sledge, George W. , Martín, Miguel , Lin, Yong , Smith, Ian C., Leo, Angelo Di , Johnston, Stephen

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: CT099-CT099

10.1158/1538-7445.am2018-ct099 Get It

Abstract Background: A recent exploratory subgroup analysis pooling data from over 1000 patients (pts) in MONARCH 2 (final analysis) and MONARCH 3 (interim analysis) demonstrated that pts with clinical characteristics that predict for worse outcome (e.g. liver metastases, progesterone receptor [PgR]-negative status, high-grade tumors) received the largest benefit from the addition of abemaciclib to endocrine therapy (ET). There is also interest in determining the extent to which abemaciclib improves progression-free survival (PFS) in pts with favorable prognostic factors (e.g. bone-only disease, long treatment-free interval [TFI]). Here we present an update of the subgroup analyses of the MONARCH 3 study using data from the preplanned final PFS analysis. Methods: Enrollment criteria and study designs were previously described (Sledge et al. J Clin Oncol. 2017; Goetz et al. J Clin Oncol. 2017). An exploratory pooled analysis was conducted using data from MONARCH 2 (NCT02107703) and the MONARCH 3 (NCT02246621) preplanned final PFS analysis to identify significant prognostic factors regardless of therapy received. Using the updated MONARCH 3 data, PFS and objective response rate (ORR) (in pts with measurable disease) were examined within the prognostic subgroups that had been previously identified as being statistically significant. Additionally, subpopulation treatment effect pattern plot (STEPP) methodology was used to evaluate the association between TFI following adjuvant ET and outcomes of NSAI alone or with abemaciclib. Results: Assessment of clinical factors from MONARCH 2 and MONARCH 3 (final PFS data) confirmed that the following factors remained significantly prognostic regardless of treatment received: bone-only disease, liver metastases, tumor grade, PgR status, and ECOG performance status. In MONARCH 3, prognosis was poor in pts with liver metastases, PgR-negative tumors, and high-grade tumors. While all subpopulations benefited from the addition of abemaciclib to ET regardless of prognosis, pts with these three poor prognostic factors received substantial benefit from abemaciclib, with PFS hazard ratios (HR) ranging from 0.4 to 0.5 and with differential improvement in ORR typically >30%. Furthermore, STEPP analysis of TFI (on the MONARCH 3 pts who had received adjuvant ET) demonstrated that pts who had a shorter TFI had a worse prognosis and received relatively greater benefit from abemaciclib plus NSAI than did pts with a longer TFI. Patients with bone-only disease or a long TFI also received benefit from abemaciclib, but to a relatively lesser extent (HR ranging from approximately 0.6 to 0.8). Conclusions: This exploratory analysis of the preplanned final PFS data from MONARCH 3 confirms previous findings that pts with poor prognostic factors may receive relatively greater benefit from the addition of abemaciclib to ET. Citation Format: Joyce O'Shaughnessy, Matthew P. Goetz, George W. Sledge, Miguel Martin, Yong Lin, Tammy Forrester, Ian C. Smith, Angelo Di Leo, Stephen Johnston. The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT099.
Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting
Shah, Paras , Patel, Vinay , George, Arvin K. , Alom, Manaf, Kozel, Zachary , Joshi, Vidhu B. , Ben‐Levi, Eran, Villani, Robert, Yaskiv, Oksana, Kavoussi, Louis R., Vira, Manish , Olsson, Carl O., Rastinehad, Ardeshir R. , Shah, Paras H , Joshi, Vidhu, Rastinehad, Ardeshir R , Moreira, Daniel M.

Mayo Clinic

BJU International | August 16, 2018 | Volume: 123 | Issue: 2 | Pages: 239-245

10.1111/bju.14515 | PMID 30113138 Get It

Objectives To investigate the impact of implementing magnetic resonance imaging (MRI) and ultrasonography fusion technology on biopsy and prostate cancer (PCa) detection rates in men presenting with clinical suspicion for PCa in the clinical practice setting. Patients and Methods We performed a review of 1 808 consecutive men referred for elevated prostate‐specific antigen (PSA) level between 2011 and 2014. The study population was divided into two groups based on whether MRI was used as a risk stratification tool. Univariable and multivariable analyses of biopsy rates and overall and clinically significant PCa detection rates between groups were performed. Results The MRI and PSA‐only groups consisted of 1 020 and 788 patients, respectively. A total of 465 patients (45.6%) in the MRI group and 442 (56.1%) in the PSA‐only group underwent biopsy, corresponding to an 18.7% decrease in the proportion of patients receiving biopsy in the MRI group ( P < 0.001). Overall PCa (56.8% vs 40.7%; P < 0.001) and clinically significant PCa detection (47.3% vs 31.0%; P < 0.001) was significantly higher in the MRI vs the PSA‐only group. In logistic regression analyses, the odds of overall PCa detection (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.29–2.35; P < 0.001) and clinically significant PCa detection (OR 2.04, 95% CI 1.48–2.80; P < 0.001) were higher in the MRI than in the PSA‐only group after adjusting for clinically relevant PCa variables. Conclusion Among men presenting with clinical suspicion for PCa, addition of MRI increases detection of clinically significant cancers while reducing prostate biopsy rates when implemented in a clinical practice setting.
Using Stress Ultrasonography to Understand the Risk of UCL Injury Among Professional Baseball Pitchers Based on Ligament Morphology and Dynamic Abnormalities
Shanley, Ellen , Smith, Matthew V. , Mayer, Braden K. , Bailey, Lane , Tokish, John M. , Kissenberth, Michael J. , Noonan, Thomas J. , Thigpen, Charles A.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 9, 2018 | Volume: 6 | Issue: 8 | Pages: No page available

10.1177/2325967118788847 | PMID 30116762 Get It

Background: Ulnar collateral ligament (UCL) injury of the elbow is a common and debilitating problem seen frequently among elite baseball pitchers. Ultrasound is a useful diagnostic tool in evaluating UCL injuries. Hypothesis: Evaluation with stress ultrasound of the elbow to measure the morphology of the UCL and the ulnohumeral joint space gapping is indicative of higher risk of UCL injury among professional baseball pitchers. Study Design: Cohort study; Level of evidence, 2. Methods: Ultrasound imaging was used to assess the medial joint laxity of the elbow of 70 asymptomatic professional baseball pitchers during spring training. Medial joint laxity and UCL morphology were assessed with OsiriX imaging software under 2 conditions—gravity valgus load and 5.5 lb of valgus load per a handheld dynamometer—with the shoulder in the maximal cocking position and the elbow in 90° of flexion. Two trials of resting position, elbow gapping, and UCL thickness were collected, measured, and averaged for data analysis. Intra- and interrater reliabilities were established and maintained, with intraclass correlation coefficients in the acceptable range for all measures (0.84-0.99). One-way analysis of variance was used to compare dominant variables between those pitchers who sustained a subsequent UCL injury and those who did not. A receiver operating curve was used to identify pitchers who, based on elbow gapping measures (by cut score), were at high risk versus low risk for UCL injury. Results: Players who went on to injure the UCL (n = 7) displayed a significantly wider opening under 5.5 lb of applied stress (6.5 ± 1.2 vs 5.3 ± 1.2 mm, P = .01) when compared with pitchers without UCL injury history (n = 63); they also presented a trend toward wider dominant arm resting joint opening (4.9 ± 1.2 vs 4.0 ± 1.1 mm, P = .07). Professional pitchers with valgus stress ulnohumeral joint gapping ≥5.6 mm (area underneath the curve, 0.77; P = .02) of the dominant arm were at a 6-times greater risk of sustaining a UCL tear requiring reconstruction within a season. Conclusion: Our data suggest that ultrasound evaluation of UCL morphology may be indicative of pitchers who are at risk of sustaining UCL injury and that it may improve player assessment.
Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency
Buchbinder, David , Cowan, Morton J. , Buzby, Jeffrey S. , Abraham, Roshini S. , Smith, Matthew J, Buzby, Jeffrey S , Smith, Matthew James , Kawahara, Misako

Mayo Clinic

Blood Advances | July 30, 2018 | Volume: 2 | Issue: 15 | Pages: 1828-1832

10.1182/bloodadvances.2018016113 | PMID 30061307 Get It

Key Points DNA ligase 4 deficiency is a defect causing lymphopenia (T-B-NK+) and a radiosensitive severe combined immunodeficiency phenotype. Flow cytometric analysis of phosphorylation/dephosphorylation states of histone H2AX allows for in-depth lineage-specific assessment.
Correction: Learning curve and competence for volumetric laser endomicroscopy in Barrett’s esophagus using cumulative sum analysis
Inamdar, Sumant , Smith, Michael S. , Rosen, Lisa, Han, Dennis , Chang, Kenneth J. , Leggett, Cadman, Lightdale, Charles J. , Sejpal, Divyesh V., Tearney, Guillermo J. , Thomas, Rebecca, Wallace, Michael B. , Leggett, Cadman L. , Wallace, Michael B , Leggett, Cadman L , Trindade, Arvind J. , Pleskow, Douglas K.

Mayo Clinic

Endoscopy | July 27, 2018 | Volume: 50 | Issue: 05 | Pages: C10-C10

10.1055/a-0658-2867 | PMID 30053760 Get It

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. , Halvorson, Alese E. , Hoke, Eva , Godwin, John E. , Couban, Stephen, Fehniger, Todd A. , Thirman, Michael J. , Tallman, Martin S. , Appelbaum, Frederick R. , Stone, Richard M. , Robinson, Sue, Chang, Julie E., Mandrekar, Sumithra J. , Byrd, John C. , Fehniger, Todd A , Smith, Mitchell R. , Chang, Julie E., Larson, Richard A. , Byrd, John C

Mayo Clinic

Blood Advances | July 20, 2018 | Volume: 2 | Issue: 14 | Pages: 1705-1718

10.1182/bloodadvances.2017015396 | PMID 30030269 Get It

Key PointsBrief lenalidomide consolidation after chemoimmunotherapy is acceptably tolerated and extends PFS and OS in CLL. FCR has superior efficacy compared with FR chemoimmunotherapy for CLL.
The Best Plastic Surgeons Are the Best Anatomists: Evaluation of a Training Method and Residents as Teachers
Noland, Shelley S. , Nuland, Sonya Van, Casey, William J., Smith, Anthony A., Pflibsen, Lacey R. , Langley, Natalie R.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 19, 2018 | Volume: 6 | Issue: 7 | Pages: e1815

10.1097/gox.0000000000001815 Get It

Developing health communication messaging for a social marketing campaign to reduce tobacco use in pregnancy among Alaska native women
Patten, Christi A. , Lando, Harry A. , Resnicow, Ken , Decker, Paul A. , Smith, Christina M. , Hanza, Marcelo M., Burhansstipanov, Linda , Scott, Matthew J. , Patten, Christi , Decker, Paul A. , Scott, Matthew

Mayo Clinic

Journal of Communication in Healthcare | July 16, 2018 | Volume: 11 | Issue: 4 | Pages: 252-262

10.1080/17538068.2018.1495929 | PMID 31548863 Get It